RXi Pharma Licenses Thermo Fisher's RNAi Sequences for Drug Programs

Dec 14, 2007

NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed RNAi sequences from Thermo Fisher Scientific to a number of target genes for use in the development of therapeutic compounds for several common diseases, RXi said today.

Under the agreement, RXi will use RNAi sequences generated by Thermo Fisher Dharmacon’s sequence selection algorithm for its rxRNA compound program, which focuses on developing therapeutics for type 2 diabetes, obesity, neurology, and oncology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Testing, Testing for Mutations

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

Hide, Nessie, Hide

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

Even More Variety

The New York Times writes about the appearance of mosaicism in healthy people.

This Week in PNAS

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Main menu